Myovant Sciences Ltd (NYSE: MYOV) was a big mover, rallying by more than 25% at the start of the final trading week of the year. The blockbuster move came on the confirmation that its parent company Sumitovant Biopharma had inked a strategic partnership with giant drug maker Pfizer Inc. (NYSE: PFE) .
Myovant- Pfizer Partnership
The agreement is for the development of treatments for prostate cancer and women's health. The deal is worth up to $4.2 billion in upfront and potential milestone payments. Under the terms of the agreement, Myovant is to receive $650 million in upfront payments. The funds are to finance the development and marketing of Relugolix, a novel treatment for advanced prostate cancer.
The two companies intend to develop and market Relugolix combination tablet, Orgovyx, Relugolix 40mg, estradiol 1.0mg, and norethindrone acetate 0.5mg, which targets women's health. Plans are underway to promote the treatment once approved and sold as a prostate cancer treatment in early 2021.
Under the strategic partnership terms, Myovant and Pfizer are to share profits and certain costs equally. Myovant will record revenues and will also be responsible for interactions with regulators and for drug supply and clinical development.
Milestone Payments
Myovant is entitled to $200 million in additional regulatory milestones should FDA approve the combination of prostate cancer drugs. It is also entitled to payments on sales milestones reaching $2.5 billion.
Investors liked the financial impact of the Pfizer partnership, which explains why Myovant exploded on a huge turnover of traded shares. The stock is up by more than 80% for the year and showing no signs of slowing down. With the stock having broken out to a new all-time high, it looks set to continue powering high at the back of ever-improving underlying fundamentals.
Pfizer tanked by more than 1% on confirming the Myovant strategic partnership. The stock has been under pressure despite sealing regulatory approval for its experimental coronavirus vaccine developed in partnership with BionTech.